JAK2 and myeloproliferative neoplasm: Multiple studies have tried to determine if JAK2 V617F allelic burden influences the risk of thrombotic events, not just in PV but in other BCR-ABL1-negative myeloproliferative neoplasms (Ph- MPNs) as well.